Frontlight ResearchEarly access
Taking peoplePhase 3
Lessening Organ Dysfunction with VITamin C in septic ARDS
Key facts
- Who runs it
- Assistance Publique Hopitaux De Paris
- Where
- France17 sites in 1 countryChoose a country to see its sites
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 814 people, planned
- Started
- 5 Nov 2024
- Expected to end
- 6 Jul 2029
- Type of study
- Interventional
- Record updated
- 22 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Patients ≥ 18 years old
- Admitted to the ICU with proven or suspected infection as the main diagnosis
- Currently treated with a continuous intravenous infusion of vasopressors (norepinephrine, epinephrine, vasopressin, dopamine, phenylephrine, angiotensin, others))
- Currently treated with high flow oxygen, CPAP OR NIV OR Invasive Ventilation
- Presenting with Acute Respiratory Distress Syndromedefined by all the following criteria: o Acute onset, i.e. within one week of an apparent clinical insult and with progression of respiratory syndrome o Bilateral opacities on chest imaging not explained by other pulmonary pathologies (e.g. pleural effusion, atelectasis, nodules, etc.) o No evidence for heart failure or volume overload o PaO2/FiO2 ≤ 200 mm Hg o PEEP ≥ 5 cm H2O
- Patient who has signed an informed and written consent whenener he/she is capable of consent, if not, Patient’s representant signed consent whenever he/she is present at inclusion
- Affiliation to a social security system or to an universal health coverage (Couverture Maladie Universelle, CMU)
- Patients under guardianship or curatorship can be included
- Patients in case of simple emergency (legal definition) or vital emergency will be included
Who cannot take part
- Received any intravenous vitamin C during this hospitalization unless incorporated in parenteral nutrition (PN) in doses standard for PN
- Previously enrolled in this study
- Previously enrolled in an interventional trial for which co-enrolment is not allowed (co-enrolment to be determined case by case)
- Treatment with Deferoxamine
- Patient with critical COVID-19 according WHO definition
- Known allergy excipients of vitamin C solution; or to one of the excipients in particular methyl parhydroxybenzoate (E218) or propyl (E216)
- Known Glucose-6-phosphate dehydrogenase (G6PD) deficiency
- 48 hours from diagnosis of ARDS
- Expected death or withdrawal of life-sustaining treatments within 48 hours
- Cardio-pulmonary resuscitation (CPR) in the past 72 hours
- Pregnancy and breast-feeding
- Hyperoxaluria
- Known kidney stones within the past 1 year
This trial is currently available in France.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To compare the effect of high-dose intravenous vitamin C vs. placebo on a composite of death or persistent organ dysfunction – defined as continued dependency on mechanical ventilation, new renal replacement therapy, or vasopressors – assessed at 28 days on ICU patients
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- LOVIT-ARDS - A Multicentre Concealed‐Allocation Parallel‐Group Blinded Randomized Controlled Trial to Ascertain the Effect of High‐Dose Intravenous Vitamin C Compared to Placebo on Mortality or Persistent Organ Dysfunction at 28 Days in Septic ARDS Patients
- Record updated
- 22 June 2026